Share on LinkedInShare on LinkedIn

ARTICLE · 12 MAY 2020

Defending Against Nonperformance Of Life Science Contracts

Sheppard
Sheppard
Contributor
Sheppard

Sheppard

Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more...

View firm profile
Explore more from Sheppard

Many life sciences contracts, including intellectual property licensing agreements, development agreements and supply agreements, contain force majeure clauses.

United StatesCoronavirus (COVID-19)

Many life sciences contracts, including intellectual property licensing agreements, development agreements and supply agreements, contain force majeure clauses.  Depending upon the language of these clauses, the COVID-19 pandemic may be an event that triggers these clauses and provides a defense to nonperformance of the contract.  Companies that are experiencing difficulties complying with or enforcing compliance with their contracts should carefully examine their contracts to determine if a force majeure clause may excuse performance.

As COVID-191 continues to rapidly sweep the globe, government agencies at all levels are being pressed to take difficult measures to curb the spread of the virus.  Such measures have included restrictions on travel and congregation that may create business disruption.  For example, as of the end of March, 2020, more than 35 states have shelter-in-place rules covering all or part of the state.2  And, even in states or localities that

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from